Get the Stockscreener App
284.02
0.85%
2.34
After Hours:
283.69
-0.33
-0.12%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $284.02, with a volume of 2.29M.
It is up +0.85% in the last 24 hours and up +9.55% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$281.68
Open:
$285
24h Volume:
2.29M
Relative Volume:
0.70
Market Cap:
$152.82B
Revenue:
$32.53B
Net Income/Loss:
$4.23B
P/E Ratio:
36.37
EPS:
7.81
Net Cash Flow:
$6.28B
1W Performance:
+2.23%
1M Performance:
+9.55%
6M Performance:
-14.77%
1Y Performance:
-9.71%
1-Day Range:
$281.64
$285.69
1-Week Range:
$273.50
$285.69
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
284.02 | 152.82B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
823.23 | 778.66B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.34 | 379.90B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
175.59 | 310.55B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Ibex Wealth Advisors Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Yahoo Finance
Amgen Inc. (NASDAQ:AMGN) Shares Sold by New England Research & Management Inc. - MarketBeat
Milestone Asset Management LLC Buys 2,685 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
AMGN: 3 Biotech Stocks Revolutionizing Healthcare - StockNews.com
Citigroup Has Lowered Expectations for Amgen (NASDAQ:AMGN) Stock Price - Defense World
Amgen's SWOT analysis: stock outlook amid obesity drug race, pipeline progress - Investing.com
Federal Court delists Regeneron patent, clearing path for Amgen biosimilar launch - Law360 Canada
Swedbank AB Buys 25,482 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards? - MSN
Forsta AP Fonden Sells 4,200 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Premenstrual Syndrome Treatment Market May See Big Move: Major - openPR
Here's Why Amgen (AMGN) is a Strong Value Stock - Yahoo Finance
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Foster Victor Wealth Advisors LLC - MarketBeat
Montrusco Bolton Investments Inc. Sells 375,906 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
BMO Capital Adjusts Price Target on Amgen to $346 From $362, Keeps Outperform Rating - Marketscreener.com
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Amgen and Celltrion settle biosimilars patent dispute - The Pharma Letter
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Twelve Points Wealth Management LLC - MarketBeat
Perigon Wealth Management LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Blue Trust Inc. - MarketBeat
2,647 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Union Bancaire Privee UBP SA - MarketBeat
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Celltrion Settlement Puts Prolia And Xgeva Biosimilars On Ice – But Only Until June - News & Insights
Bensler LLC Sells 3,489 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Matrix Asset Advisors Inc. NY Has $24.25 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (NASDAQ:AMGN) Price Target Cut to $295.00 by Analysts at Citigroup - MarketBeat
Analyst Expectations For Amgen's Future - Benzinga
BankPlus Wealth Management LLC Takes $475,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Citigroup Adjusts Price Target on Amgen to $295 From $310, Maintains Neutral Rating - Marketscreener.com
Lebenthal Global Advisors LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Foundations Investment Advisors LLC Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Biotech Giant Amgen Launches Media Review 07/22/2024 - MediaPost Communications
Drive Wealth Management LLC Invests $236,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (AMGN) Expected to Announce Earnings on Tuesday - MarketBeat
This Is What Whales Are Betting On Amgen - Benzinga
Amgen Deal Blocks Celltrion's Bone-Drug Biosimilars Until June - Bloomberg Law
Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now? - MSN
Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer - GlobeNewswire Inc.
Baldwin Wealth Partners LLC MA Sells 1,282 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Granite Group Advisors LLC Has $2.29 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stake Cut by Marshall Financial Group LLC - MarketBeat
Exchange Traded Concepts LLC Purchases 1,464 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen opens new drug substance facility in North Carolina, US - Yahoo Finance
Avior Wealth Management LLC Cuts Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Blue Square Asset Management LLC Acquires 7,277 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Jamison Private Wealth Management Inc. Buys 997 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Alan B Lancz & Associates Inc. - MarketBeat
DGS Capital Management LLC Has $392,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by SG Americas Securities LLC - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):